Last reviewed · How we verify
Basal bolus insulin
At a glance
| Generic name | Basal bolus insulin |
|---|---|
| Also known as | glargine, detemir |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Relapse Among Diabetic Ketoacidosis Patients Maintained Basal Bolus Insulin Administration in Combination With Continuous Intravenous Insulin Infusion VS Non Maintaining Basal Insulin Patients (NA)
- A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes (NA)
- SHOrt-term Glycemic Control for Reducing Post-SURGical Complications (NA)
- App-Based Certified Diabetes Education Therapy (AB-CDE) (NA)
- Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes" (PHASE3)
- A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |